Closing

Do GIP/GLP-1 & amylin agonists improve cardiovascular events versus placebo?

Mostly studied in type 2 & unspecified diabetes. Also asked against other treatments.

Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →

Where the evidence stands

A coin flip. So far, one result, not yet repeated.

NoUnsureYes
Belief
0.50 (range 0.25–0.70)
Trials for
1
Trials against
0
Inconclusive
0

Already under way

The evidence so far

Registered trials
23
With posted results
3
Published papers
11

Of 5 decided analyses: 3 favor gip/glp-1 & amylin agonists, 1 find no difference, 1 favor the comparator.

Papers

Trials

See every trial in the evidence map →